https://www.35pharma.com/fr-fr https://www.35pharma.com https://www.35pharma.com/fr-fr/news https://www.35pharma.com/news https://www.35pharma.com/fr-fr/pipeline https://www.35pharma.com/pipeline https://www.35pharma.com/fr-fr/technology https://www.35pharma.com/technology https://www.35pharma.com/fr-fr/about-us https://www.35pharma.com/about-us https://www.35pharma.com/fr-fr/careers https://www.35pharma.com/careers https://www.35pharma.com/news/35pharma-announces-oral-presentation-of-hs235-pre-clinical-data-in-models-of-pulmonary-hypertension-at-ers-2025 https://www.35pharma.com/fr-fr/news/35pharma-announces-oral-presentation-of-hs235-pre-clinical-data-in-models-of-pulmonary-hypertension-at-ers-2025 https://www.35pharma.com/news/35pharma-announces-oral-presentation-of-hs235-pre-clinical-data-in-obese-hfpef-at-obesityweek-r-2024 https://www.35pharma.com/fr-fr/news/35pharma-announces-oral-presentation-of-hs235-pre-clinical-data-in-obese-hfpef-at-obesityweek-r-2024 https://www.35pharma.com/news/35pharma-appoints-guy-braunstein-md-phd-to-its-board-of-directors https://www.35pharma.com/fr-fr/news/35pharma-appoints-guy-braunstein-md-phd-to-its-board-of-directors https://www.35pharma.com/news/35pharma-cleared-to-initiate-clinical-development-of-hs235-novel-activin-and-gdf-inhibitor-for-cardiometabolic-disease-and-obesity-yzxmv https://www.35pharma.com/fr-fr/news/35pharma-cleared-to-initiate-clinical-development-of-hs235-novel-activin-and-gdf-inhibitor-for-cardiometabolic-disease-and-obesity-yzxmv https://www.35pharma.com/news/35pharma-closes-series-c-financing-to-advance-clinical-pipeline-of-activin-inhibitors-for-pulmonary-hypertension-cardiometabolic-disease-and-obesity-2-4abwj https://www.35pharma.com/fr-fr/news/35pharma-closes-series-c-financing-to-advance-clinical-pipeline-of-activin-inhibitors-for-pulmonary-hypertension-cardiometabolic-disease-and-obesity-2-4abwj https://www.35pharma.com/news/35pharma-oral-presentation-at-cvct-2025 https://www.35pharma.com/fr-fr/news/35pharma-oral-presentation-at-cvct-2025 https://www.35pharma.com/news/35pharma-oral-presentation-at-obesityweek-2025 https://www.35pharma.com/fr-fr/news/35pharma-oral-presentation-at-obesityweek-2025 https://www.35pharma.com/news/35pharma-presents-hs235-pre-clinical-heart-failure-and-pulmonary-hypertension-data-in-moderated-poster-session-at-aha-2025 https://www.35pharma.com/fr-fr/news/35pharma-presents-hs235-pre-clinical-heart-failure-and-pulmonary-hypertension-data-in-moderated-poster-session-at-aha-2025 https://www.35pharma.com/news/35pharma-to-be-acquired-by-gsk https://www.35pharma.com/fr-fr/news/35pharma-to-be-acquired-by-gsk https://www.35pharma.com/news/35pharma-to-participate-in-upcoming-investor-conferences-in-march https://www.35pharma.com/fr-fr/news/35pharma-to-participate-in-upcoming-investor-conferences-in-march https://www.35pharma.com/fr-fr/news/35pharma-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference https://www.35pharma.com/news/35pharma-to-receive-promising-biotech-company-of-the-year-award-from-biotecanadas-2025-gold-leaf-awards https://www.35pharma.com/fr-fr/news/35pharma-to-receive-promising-biotech-company-of-the-year-award-from-biotecanadas-2025-gold-leaf-awards https://www.35pharma.com/publications/hs235-a-novel-activin-signaling-inhibitor-is-highly-efficacious-in-preclinical-models-of-pulmonary-hypertension-and-heart-failure https://www.35pharma.com/fr-fr/publications/hs235-a-novel-activin-signaling-inhibitor-is-highly-efficacious-in-preclinical-models-of-pulmonary-hypertension-and-heart-failure https://www.35pharma.com/publications/hs235-a-novel-activin-signaling-inhibitor-is-highly-efficacious-in-preclinical-models-of-pulmonary-hypertension-ph-and-heart-failure-hf https://www.35pharma.com/fr-fr/publications/hs235-a-novel-activin-signaling-inhibitor-is-highly-efficacious-in-preclinical-models-of-pulmonary-hypertension-ph-and-heart-failure-hf https://www.35pharma.com/publications/hs235-a-novel-lean-mass-preserving-treatment-for-obesogenic-hf-with-preserved-ejection-fraction https://www.35pharma.com/fr-fr/publications/hs235-a-novel-lean-mass-preserving-treatment-for-obesogenic-hf-with-preserved-ejection-fraction https://www.35pharma.com/publications/hs235-a-precision-engineered-activin-and-gdf-ligand-trap-is-a-novel-lean-mass-preserving-treatment-for-obesity https://www.35pharma.com/fr-fr/publications/hs235-a-precision-engineered-activin-and-gdf-ligand-trap-is-a-novel-lean-mass-preserving-treatment-for-obesity https://www.35pharma.com/publications/precision-engineered-activin-and-gdf-ligand-trap-hs235---a-novel-lean-mass-preserving-treatment-for-obesity https://www.35pharma.com/fr-fr/publications/precision-engineered-activin-and-gdf-ligand-trap-hs235---a-novel-lean-mass-preserving-treatment-for-obesity https://www.35pharma.com/publications/precision-engineered-activin-and-gdf-ligand-trap-hs235-a-novel-lean-mass-preserving-treatment-for-obesity https://www.35pharma.com/fr-fr/publications/precision-engineered-activin-and-gdf-ligand-trap-hs235-a-novel-lean-mass-preserving-treatment-for-obesity https://www.35pharma.com/publications/precision-engineered-activin-and-gdf-ligand-trap-hs235-a-novel-lean-mass-preserving-treatment-for-obesity-2 https://www.35pharma.com/fr-fr/publications/precision-engineered-activin-and-gdf-ligand-trap-hs235-a-novel-lean-mass-preserving-treatment-for-obesity-2